The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | CPX-351 shows promising results in poor risk AML (t-AML and MRC-AML)
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses a report from a multicentric French cohort. This study analyzed the efficacy of a liposomal formulation of cytarabine and daunorubicin (CPX-351) in a real-life setting in patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). Prof. Cluzeau highlights the excellent results, confirming the efficacy and safety of CPX-351, including in patients with unfavorable mutations. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
